StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) company profile

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3025% above fair value
$1415.55−16.12 (-1.13%)

Close on Nov 17, 2026Market cap $1.33TP/E 45.9Yield 0.44%

About Eli Lilly

Pharmaceutical Preparations, SIC 2834

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products across a single operating segment. Its portfolio spans therapeutic treatments in cardiometabolic health, oncology, immunology, and neuroscience, addressing conditions such as diabetes, obesity, various cancers, and autoimmune disorders. The company provides its therapies to patients globally, distributing primarily through wholesale distributors, retail pharmacies, and hospitals, while engaging directly with healthcare professionals and consumers via platforms such as LillyDirect.

The enterprise operates manufacturing and distribution facilities across the United States, Puerto Rico, Europe, and Asia. It markets and commercializes its medical therapies in approximately 90 countries worldwide. The company traces its origins to Indianapolis, Indiana, where its predecessor drug manufacturing business was initially established and where its corporate headquarters remain situated.

Summary of the business section of Eli Lilly's latest annual report, written by StockData.

Company profile

Company

Legal name
ELI LILLY & Co
Founded
1876
Headquarters
Indianapolis, IN
Address
Lilly Corporate Ctr, Drop Code 1094 46285
Phone
(317) 276-2000
Employees
50,000, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Indiana
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Indianapolis, Indiana

Stock & identifiers

Ticker
LLY
Exchange
NYSE
Shares outstanding
941M, Oct 26, 2026
Public float
$807.89B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
2-for-1, Oct 16, 1997; 2-for-1, Dec 21, 1995; 2-for-1, May 1, 1989; 2-for-1, Jan 30, 1986
SEC CIK
59478
CUSIP
532457108
ISIN
US5324571083
FIGI
BBG000BNBDC2
Share class FIGI
BBG001S5STL8
LEI
FRDRIPF3EKNDJ2CQJL29
EIN
35-0470950

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
David A. RicksPresident, Chair, and CEO, Director685,273
Patrik JonssonEVP & President, LLY Int'l54,075
Eric DozierEVP, Chief People Officer15,933
Anat HakimEVP, GC & Secretary45,562
Edgardo HernandezEVP & Pres., Mfg. Operations48,364
Daniel SkovronskyEVP, CS&PO & Pres. LRL235,569
Lucas MontarceEVP & CFO17,191
Adrienne S. BrownEVP, President LLY Imm9,894
Kenneth L. CusterEVP & President, Card Met Hlth11,935
Melissa SeymourEVP, Global Quality1,038
Donald A. ZakrowskiSVP, Finance, & CAO3,261
Ilya YuffaEVP&Pres, LLY USA&Global Capab29,804
Diogo RauEVP & CIDO26,397
Naarden Jacob VanEVP,Pres LLY Oncology&HdCorpBD36,271
Carole HoEVP & Pres, Lilly Neuroscience–
Anne E. WhiteEVP & Pres, Lilly Neuroscience74,210
Katherine BaickerDirector23,815
Gabrielle SulzbergerDirector3,188
Juan R. LucianoDirector17,148
J. Erik FyrwaldDirector75,719
Jon R. MoellerDirector473
Mary Lynne HedleyDirector2,528
Ralph AlvarezDirector56,783
William G. Kaelin JrDirector22,139
Kimberly H. JohnsonDirector3,452

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$36.70M$75.19M$10.93M$671$154
FY2024$29.24M$80.58M$6.09M$478$123
FY2023$26.57M$120.87M$7.84M$359$118
FY2022$21.40M$64.09M$5.77M$223$125
FY2021$21.51M$75.71M$4.73M$166$117
FY2020$23.71M$51.25M$6.79M$131$102

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
David A. Ricks
Chair, President, and Chief Executive Officer
$1.70M$23.33M$6.49M$5.19M$36.70M+25%
Lucas Montarce
Executive Vice President and Chief Financial Officer
$1.00M$5.00M$2.18M$303.32K$8.48M+188%
Daniel M. Skovronsky, M.D., Ph.D.
Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Labs
$1.49M$12.00M$3.25M$1.05M$17.79M+41%
Anat Hakim
Executive Vice President, General Counsel and Secretary
$1.00M$6.00M$2.18M$665.52K$9.85M+32%
Jake Van Naarden
Executive Vice President and President, Lilly Oncology and Head of Corporate Business Development
$920.19K$4.50M$2.01M$159.89K$7.59M+31%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“At the end of 2025, we employed approximately 50,000 people, including approximately 27,000 employees outside the U.S.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jun 2, 2026DelistingNotice of delisting from exchange (Form 25)
Nov 7, 2025Tender offerThird-party tender offer for the company's shares
Jun 25, 2025Tender offerThird-party tender offer for the company's shares
Jun 2, 2025DelistingNotice of delisting from exchange (Form 25)
Jul 19, 2024Tender offerThird-party tender offer for the company's shares
Oct 13, 2023Tender offerThird-party tender offer for the company's shares
Jul 13, 2023Tender offerThird-party tender offer for the company's shares
Jun 30, 2023Tender offerThird-party tender offer for the company's shares
Oct 31, 2022Tender offerThird-party tender offer for the company's shares
Mar 2, 2022DelistingNotice of delisting from exchange (Form 25)
Sep 14, 2021ListingRegistration of securities on an exchange (Form 8-A)
Dec 22, 2020Tender offerThird-party tender offer for the company's shares
Jan 22, 2020Tender offerThird-party tender offer for the company's shares
Nov 7, 2019ListingRegistration of securities on an exchange (Form 8-A)
Oct 25, 2019Name changeName changed from LILLY ELI & CO to ELI LILLY & Co
Mar 15, 2019Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 17, 2019Tender offerThird-party tender offer for the company's shares
May 23, 2018Tender offerThird-party tender offer for the company's shares
Jan 31, 2017Tender offerThird-party tender offer for the company's shares
Jun 16, 2015DelistingNotice of delisting from exchange (Form 25)
Jun 2, 2015ListingRegistration of securities on an exchange (Form 8-A)
Jan 7, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 26, 2008Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 14, 2008Tender offerThird-party tender offer for the company's shares
Jan 31, 2007Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 29, 2006DelistingNotice of delisting from exchange (Form 25)
Dec 22, 2003MergerRegistration of securities for a merger or exchange offer (S-4)
Jul 23, 1998ListingRegistration of securities on an exchange (Form 8-A)
Jan 10, 1996ListingRegistration of securities on an exchange (Form 8-A)
Sep 13, 1995MergerRegistration of securities for a merger or exchange offer (S-4)

See a number that looks wrong?